Sofosbuvir for Previously Untreated Chronic Hepatitis C Infection
Eric Lawitz(The University of Texas at San Antonio Health Science Center), Edward Gane(University of Auckland), Aasim Sheikh(GI Specialists of Georgia (United States)), Lisa M. Nyberg(Kaiser Permanente San Diego Medical Center), K. Rajender Reddy(University of Pennsylvania Health System), Tarek Hassanein, Mitchell Davis(Digestive CARE), Stuart C. Gordon(Henry Ford Health System), William T. Symonds(Gilead Sciences (United States)), M. Rodríguez‐Torres(Puerto Rico Community Foundation), Deyuan Jiang(Gilead Sciences (United States)), John G. McHutchison(Gilead Sciences (United States)), Ira M. Jacobson(Cornell University), Zobair M. Younossi(Inova Health System), Sarah Arterburn(Gilead Sciences (United States)), David Wyles(University of California San Diego), G. Mani Subramanian(National Institutes of Health), Kris V. Kowdley(Washington State University Spokane), Zeid Kayali(Arrowhead Regional Medical Center), Diana M. Brainard(Gilead Sciences (United States)), John McNally(Gilead Sciences (United States)), Alessandra Mangia(Casa Sollievo della Sofferenza), Robert H. Hyland(Gilead Sciences (United States)), Michael Schultz
Cited by 1,782
Related Papers
Pioglitazone, Vitamin E, or Placebo for Nonalcoholic Steatohepatitis
|New England Journal of Medicine|2010|3.3k
A multisociety Delphi consensus statement on new fatty liver disease nomenclature
|Hepatology|2023|2.9k
A multisociety Delphi consensus statement on new fatty liver disease nomenclature
|Journal of Hepatology|2023|2.7k